Analysts who follow Mersana Therapeutics Inc (MRSN) on average expect it to decline -13.48% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns the stock an Analyst Ranking of 18, which means it ranks higher than 18 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating MRSN a Buy today. Find out what this means to you and get the rest of the rankings on MRSN!